Company Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Mereo BioPharma Group plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-16 pm EDT			5-day change	1st Jan Change
3.27 ^USD	+3.15%		0.00%	+41.56%

May. 16	European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	MT
May. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Number of employees: 33

USD in Million	2022	Weight	2023	Weight	Delta
Rare Disease Therapies 100.0 %	0	nan %	12	100.0 %	-

Managers	Title	Age	Since
John P. Richard FOU	Founder	66	15-02-28
Denise Scots-Knight FOU	Founder	64	15-07-09
Charles Sermon FOU	Founder	55	15-02-28
Christine Fox DFI	Director of Finance/CFO	43	21-01-30
Michael Wyzga CHM	Chairman	69	19-04-22
Suba Krishnan CTO	Chief Tech/Sci/R&D Officer	59	20-12-06
John Lewicki CTO	Chief Tech/Sci/R&D Officer	72	20-06-30
Richard Francis PRN	Corporate Officer/Principal	-	19-07-31
Wills Hughes-Wilson PRN	Corporate Officer/Principal	53	18-02-28

Members of the board	Title	Age	Since
Michael Wyzga CHM	Chairman	69	19-04-22
Marc J. Yoskowitz BRD	Director/Board Member	-	22-11-09
Deepa Pakianathan BRD	Director/Board Member	59	19-04-22
Denise Scots-Knight FOU	Founder	64	15-07-09
Anders Olof Adolf Ekblom BRD	Director/Board Member	70	15-06-30
Pierre Jacquet BRD	Director/Board Member	57	21-09-19
Justin Roberts BRD	Director/Board Member	-	22-11-09
Annalisa Jenkins BRD	Director/Board Member	58	22-11-09
Jeremy Bender BRD	Director/Board Member	52	20-09-30
Daniel Shames BRD	Director/Board Member	-	22-11-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	643,204,794	301,926,833 ( 46.94 %)	0	46.94 %

Name	Equities	%	Valuation
Rubric Capital Management LP 9.669 %	13,552,997	9.669 %	38 M $
Rubric Capital Management LP 9.669 %	13,552,997	9.669 %	38 M $
Adage Capital Management LP 7.170 %	10,050,000	7.170 %	28 M $
Adage Capital Partners GP LLC 6.655 %	9,328,739	6.655 %	26 M $
Mangrove Partners 6.244 %	8,752,893	6.244 %	25 M $
Rock Springs Capital Management LP 5.808 %	8,142,109	5.808 %	23 M $
683 Capital Management LLC 4.102 %	5,750,000	4.102 %	16 M $
Janus Henderson Investors US LLC 3.653 %	5,120,573	3.653 %	14 M $
Alkeon Capital Management LLC (13F Subfiler) 3.023 %	4,238,100	3.023 %	12 M $
Suvretta Capital Management LLC 2.606 %	3,653,494	2.606 %	10 M $

Name	Equities	%	Valuation
Soleus Capital Management LP 8.376 %	48,887,095	8.376 %	27 M $
Rubric Capital Management LP 5.474 %	31,950,000	5.474 %	18 M $
Denise Scots-Knight 0.0192 %	112,082	0.0192 %	62 990 $
Phase4 Partners Ltd. 0.004536 %	26,475	0.004536 %	14 879 $
Anders Olof Adolf Ekblom 0.001300 %	7,588	0.001300 %	4 264 $
John Lewicki 0.000624 %	3,640	0.000624 %	2 046 $
Christine Fox 0.000428 %	2,500	0.000428 %	1 405 $
Wills Hughes-Wilson 0.000262 %	1,530	0.000262 %	860 $
Marc J. Yoskowitz 0.000000 %	0	0.000000 %	- $
Michael Wyzga 0.000000 %	0	0.000000 %	- $

Mereo BioPharma Group Plc

1 Cavendish Place 4th Floor

W1G 0QF, London

+44 33 3023 7300

http://www.mereobiopharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.581 GBP

Average target price

4.959 GBP

Spread / Average Target

+92.17%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MEREO BIOPHARMA GROUP PLC	+41.56%	458M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+0.44%	22.28B
BIONTECH SE	-11.90%	22.41B
GENMAB A/S	-4.59%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs